BIO

Bio-Rad (BIO) reported earnings 30 days ago. What's next for the stock?

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that its Chief Financial Officer, Roop K. Lakkaraju, will participate in a fireside chat event during Wells Fargo's 21st Annual Healthcare Conference on Wednesday, September 9, 2026, at 3:45 PM Eastern Time (12:45 PM Pacific Time). A live webcast and subsequent replay of the event will be available in the Investor Relati.

BIO's digital PCR gains and recurring diagnostics base support growth, but a 40.2X forward P/E and muted 2026 outlook keep valuation risk in focus.

BIO's 19.1% monthly rally is backed by digital PCR gains and steadier diagnostics, but weak Life Science demand and a rich valuation loom.

Explore Bio-Rad's (BIO) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.

Bio-Rad Laboratories NYSE: BIO reported second-quarter revenue of approximately $651 million, essentially flat from $652 million a year earlier on a reported basis and down 1.9% on a currency-neutral basis, as continued softness in academic research markets weighed on its Life Science segment.

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the second quarter ended June 30, 2026. Norman Schwartz, Bio-Rad's Chairman and Chief Executive Officer, stated: “Second-quarter reported revenue was flat year-over-year, with growth in Clinical Diagnostics offset by continued softness in Life Science. Despite Life Science headwinds, our digital PCR.

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the second quarter of 2026 on Tuesday, August 4, 2026, following the close of the market. Management will discuss these results in a conference call scheduled for 2:00 PM Pacific Time (5:00 PM Eastern Time) that day. To participate, dial (800) 715-9871 within the U.S. or (646) 307-1963 outside the U.

I assign a "Buy" rating to Bio-Rad Laboratories, citing activist involvement. Elliott's entry signals meaningful re-rating potential, assuming further operational improvements; BIO is already shifting M&A focus to revenue-generating bolt-ons and rationalizing R&D spend. The potential monetization of BIO's Sartorius stake, worth over $5 billion, appears more likely with Elliott's involvement, since the activist is also a shareholder of Sartorius.

U.S. biotechnology industry trade group BIO worked with the Food and Drug ​Administration on plans announced on Monday to speed ‌clinical trials and expects the next initiative will aim to standardize the agency's review of drug applications, CEO John Crowley ​said on Tuesday.